Literature DB >> 10532589

Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin.

E Di Carlo1, M G Diodoro, K Boggio, A Modesti, M Modesti, P Nanni, G Forni, P Musiani.   

Abstract

Morphologic examinations of mammary neoplasias arising in BALB/c (H-2d) mice carrying the activated rat HER-2/neu oncogene (BALB-NeuT), and in FVB (H-2q) mice bearing the wild-type proto-oncogene (FVB-NeuN), indicate that both conditions result in a very human-like lobular carcinoma of alveolar type, whose histotype is the result of the preferential expression of HER-2/neu products in the epithelium of lobular ducts and lobules. Detailed analysis of tumor progression indicates that transition from lobular hyperplasia to overt carcinoma is associated with a high epithelial proliferation rate, as assessed by anti-proliferating cell nuclear antigen immunostaining, and coincides with the activation and maximal extension of tumor angiogenic process as assessed by microvessel count (anti-CD31), anti-beta3 integrin, and anti-laminin immunostaining. Neovascularization is accompanied by vascular endothelial cell growth factor and basic fibroblast growth factor production by hyperplastic epithelial cells. By contrast with the BALB-NeuT tumors, E-cadherin expression is almost nonexistent in those arising in FVB-NeuN mice and this may explain their high metastatic potential. Despite their different kinetics, however, the lung metastases observed in both strains are histologically similar and resemble the primary tumor. Both strains can thus be proposed as models for "in vivo" investigation of the origin and progression of the alveolar type of lobular mammary carcinoma and the testing of new therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10532589

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  29 in total

1.  A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth.

Authors:  Lars Holmgren; Elena Ambrosino; Olivier Birot; Carl Tullus; Niina Veitonmäki; Tetyana Levchenko; Lena-Maria Carlson; Piero Musiani; Manuela Iezzi; Claudia Curcio; Guido Forni; Federica Cavallo; Rolf Kiessling
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-05       Impact factor: 11.205

Review 2.  A critical analysis of current in vitro and in vivo angiogenesis assays.

Authors:  Carolyn A Staton; Malcolm W R Reed; Nicola J Brown
Journal:  Int J Exp Pathol       Date:  2009-06       Impact factor: 1.925

3.  Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy.

Authors:  John Stagg; Sherene Loi; Upulie Divisekera; Shin Foong Ngiow; Helene Duret; Hideo Yagita; Michele W Teng; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-11       Impact factor: 11.205

4.  Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.

Authors:  Annalisa Astolfi; Lorena Landuzzi; Giordano Nicoletti; Carla De Giovanni; Stefania Croci; Arianna Palladini; Silvano Ferrini; Manuela Iezzi; Piero Musiani; Federica Cavallo; Guido Forni; Patrizia Nanni; Pier-Luigi Lollini
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

5.  Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help.

Authors:  Jason C Steel; Charmaine A Ramlogan; Ping Yu; Yoshio Sakai; Guido Forni; Thomas A Waldmann; John C Morris
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

6.  Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis.

Authors:  Yoshihiro Hayakawa; Stefania Rovero; Guido Forni; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-16       Impact factor: 11.205

Review 7.  Genetically engineered mouse models of mammary intraepithelial neoplasia.

Authors:  R D Cardiff; D Moghanaki; R A Jensen
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

8.  Sca-1 identifies the tumor-initiating cells in mammary tumors of BALB-neuT transgenic mice.

Authors:  Cristina Grange; Stefania Lanzardo; Federica Cavallo; Giovanni Camussi; Benedetta Bussolati
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

9.  The inhibition of early stages of HER-2/neu-mediated mammary carcinogenesis by dietary n-3 PUFAs.

Authors:  Lisa D Yee; Deepak Agarwal; Thomas J Rosol; Amy Lehman; Min Tian; Jennifer Hatton; Jessica Heestand; Martha A Belury; Steven K Clinton
Journal:  Mol Nutr Food Res       Date:  2012-12-05       Impact factor: 5.914

10.  A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent.

Authors:  C De Lorenzo; A Tedesco; G Terrazzano; R Cozzolino; P Laccetti; R Piccoli; G D'Alessio
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.